![Donald Emil Ganem](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Donald Emil Ganem
Director Ejecutivo en Via Nova Therapeutics, Inc. .
Cargos activos de Donald Emil Ganem
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Via Nova Therapeutics, Inc.
![]() Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Director/Miembro de la Junta | - | - |
Director Ejecutivo | - | - | |
Presidente | - | - |
Historial de carrera de Donald Emil Ganem
Estadísticas
Internacional
Estados Unidos | 2 |
Operativa
Director/Board Member | 1 |
Chief Executive Officer | 1 |
President | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Via Nova Therapeutics, Inc.
![]() Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Health Technology |
- Bolsa de valores
- Insiders
- Donald Emil Ganem
- Experiencia